查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1373917

子宫癌治疗和诊断市场，按类型、治疗、主要测试、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测

Uterine Cancer Therapies and Diagnostic Market, By Type, By Treatment, By Major Tests, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 302 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022 年子宫癌治疗与诊断市场规模为 220.619 亿美元，2023 年至 2030 年复合CAGR为 6.3%。

子宫癌治疗与诊断市场-市场动态

对子宫癌的认识和技术创新预计将推动市场成长

医疗保健专业人员和患者现在意识到子宫癌的流行，并且对了解可用于治疗这些疾病的疗法也变得更加感兴趣。与此一致的是，这是全球市场子宫癌治疗和诊断的主要突出因素。然而，昂贵的治疗程序和不良副作用是可能阻碍市场成长的一些主要因素。此外，城市人口医疗保健支出的大幅增加以及政府改善医疗基础设施的措施也推动了子宫癌治疗和诊断市场的发展。此外，由于医疗保健服务的技术创新和子宫癌新药的推出，鼓励患者投资于适当的治疗和诊断。

子宫癌治疗和诊断市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球子宫癌治疗和诊断市场在预测期内（2023-2030 年）每年将以 6.3% 左右的CAGR增长

由于子宫内膜腺癌负担日益增加，子宫癌治疗和诊断行业预计将以显着的速度增长。

根据类型细分，预计子宫内膜癌将在 2022 年显示最大的市场份额

从治疗细分来看，化疗是2022年的主导类型

子宫内膜癌发生率上升的主要原因是女性肥胖率的增加，预计将加速市场成长。

子宫癌治疗与诊断市场区隔分析：

全球子宫癌治疗和诊断市场根据类型、治疗、主要测试和地区进行细分。

市场依类型分为两类：子宫内膜癌和子宫肉瘤。在预测期内，子宫内膜癌细分市场可能会占据最高的市场份额。子宫内膜癌是发生在子宫内膜的独特子宫癌类别之一。评估子宫内膜癌特异性诊断技术和工具（包括液体活检或尖端成像技术）的进步，可以深入了解该细分市场的诊断市场。

根据治疗方法，市场分为五类：免疫治疗、手术、化疗、后续治疗和放射治疗。化疗领域的市占率成长最快，因为化疗是子宫癌治疗的重要组成部分，特别是对于转移性或晚期病例。化疗物质用于杀死或减缓快速分裂的癌细胞的生长

子宫癌治疗与诊断市场 - 地理洞察

北美未来可能主导子宫癌治疗和诊断市场。一般民众的意识不断增强和发病率上升是该地区市场成长的主要原因。此外，经济中新技术的更快采用正在推动所研究市场的整体成长。此外，由于欧洲地区女性生活方式的变化，欧洲地区被认为主导了市场。在老年女性中，子宫癌的盛行率更为常见。

子宫癌治疗与诊断市场-竞争格局：

子宫癌治疗和诊断市场竞争激烈，许多医疗器材製造商、製药公司和研究机构积极参与。诊断和治疗技术的进步以及新进业者继续影响着市场。此外，对于癌症治疗和筛检的支持性政府措施和医疗保健政策，促进了子宫癌治疗和诊断的整体市场成长。在肿瘤学领域，持续的研究和开发活动促进了诊断工具和创新疗法的开发。例如，2023 年 6 月，辉瑞宣布 DUAVEE (R) 是一种基于雌激素的更年期激素疗法，在自愿召回后，现已在美国重新有库存，且包装更好。此次召回是由于对包装的担忧，而不是基于对产品本身的任何安全和功效的担忧。

最近的发展：

例如，2021年4月，罗氏宣布美国食品药物管理局（FDA）核准VENTANA MMR RxDx Panel用于晚期或復发性子宫内膜癌患者。测试可以检查是否有资格接受 JEMPERLI (dostarlimab-gxly) 单药治疗的患者，这是一种来自葛兰素史克 (GSK) 的抗 PD1 免疫疗法，已获得 FDA 批准。

目录

第 1 章：子宫癌治疗与诊断市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场摘录
    • 按类型分類的子宫癌治疗和诊断市场摘录
    • 子宫癌治疗与诊断市场摘录（依治疗）
    • 主要测试的子宫癌治疗和诊断市场摘录
    • 按国家/地区分類的子宫癌治疗和诊断市场摘录
    • 按地区分類的子宫癌治疗和诊断市场摘录
  • 竞争洞察

第 3 章：子宫癌治疗和诊断主要市场趋势

  • 子宫癌治疗与诊断市场驱动因素
    • 市场驱动因素的影响分析
  • 子宫癌治疗与诊断市场限制
    • 市场限制影响分析
  • 子宫癌治疗与诊断市场机会
  • 子宫癌治疗与诊断市场未来趋势

第 4 章：子宫癌治疗与诊断产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：子宫癌治疗与诊断市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：子宫癌治疗与诊断市场模式

  • 2022 年子宫癌治疗与诊断市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：子宫癌治疗与诊断市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 子宫内膜癌
    • 子宫肉瘤

第 8 章：子宫癌治疗与诊断市场 - 按治疗分类

  • 概述
    • 按处理方式分類的细分市场占有率分析
    • 免疫疗法
    • 手术
    • 化疗
    • 后续治疗
    • 放射治疗

第 9 章：子宫癌治疗和诊断市场 - 通过主要测试

  • 概述
    • 透过主要测试进行的细分市场份额分析
    • 子宫腔镜检查
    • 活检
    • 骨盆腔超音波检查
    • CT扫描
    • 扩张和刮除术

第 10 章：子宫癌治疗和诊断市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美子宫癌治疗和诊断主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按类型）
    • 北美市场规模与预测（以不同处理方式）
    • 透过主要测试得出的北美市场规模和预测
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲子宫癌治疗和诊断主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模与预测（按处理方式）
    • 透过主要测试得出的欧洲市场规模和预测
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区子宫癌治疗和诊断主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区市场规模与预测（以不同处理方式）
    • 透过主要测试得出的亚太市场规模和预测
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲子宫癌治疗和诊断主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模与预测（以不同处理方式）
    • 透过主要测试得出的拉丁美洲市场规模和预测
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲子宫癌治疗和诊断主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按类型）
    • 中东及非洲市场规模及预测（依不同处理方式）
    • 中东和非洲市场规模及预测（透过主要测试）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 子宫癌治疗与诊断产业

  • 竞争仪表板
  • 公司简介
    • Ariad Pharmaceuticals
    • AstraZeneca PLC
    • Siemens Healthcare Inc.
    • Abbott Laboratories
    • Eli Lilly and Company
    • Becton Dickinson & co
    • Roche Ltd.
    • GlaxoSmithKline Plc
    • Ability Pharma
    • Merck & Co.
    • BioMerieux SA
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Sanofi

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV1805

REPORT HIGHLIGHT

Uterine cancer therapies and diagnostic market size was valued at USD 22,061.9 Million in 2022, expanding at a CAGR of 6.3% from 2023 to 2030.

Uterine cancer is a cancer that affects the female reproductive system. It is a malignant tumor that starts in the uterus cells and has the potential to spread to other body parts. Uterine cancer therapeutics primarily includes numerous treatment modalities, such as radiation therapy, hormone therapy, targeted therapy, chemotherapy, and surgery. Additionally, the treatment choice depends on various factors such as the patient's overall health, the type of uterine cancer, and the stage of the cancer.

Uterine Cancer Therapies and Diagnostic Market- Market Dynamics

Awareness of uterine cancer and technical innovations are expected to drive market growth

Healthcare professionals and patients are now aware of the prevalence of uterine cancer, and additionally becoming more actively interested in learning about the therapies available for the treatment of these conditions. In line with this, this is the main prominent factor for uterine cancer therapies and diagnostics in the global market. However, costly treatment procedures and adverse side effects are some of the major factors likely to hinder market growth. Furthermore, the market for uterine cancer therapies and diagnostics is being fueled by the significant increment in healthcare spending among the urban population and government initiatives for better healthcare infrastructure. Moreover, patients are being encouraged to invest in proper treatments and diagnostics as an outcome of technical innovations in healthcare services and the introduction of novel drugs regarding uterine cancer.

Uterine Cancer Therapies and Diagnostic Market- Key Insights

As per the analysis shared by our research analyst, the global uterine cancer therapies and diagnostic market is estimated to grow annually at a CAGR of around 6.3% over the forecast period (2023-2030)

The uterine cancer therapies and diagnostic industry is projected to grow at a significant rate due to the growing burden of endometrial adenocarcinoma.

Based on type segmentation, endometrial carcinomas was predicted to show maximum market share in the year 2022

Based on treatments segmentation, chemotherapy was the leading type in 2022

The prime factor responsible for the growing incidence of endometrium carcinoma is increasing obesity among women is projected to accelerate the market growth.

Uterine Cancer Therapies and Diagnostic Market- Segmentation Analysis:

The global uterine cancer therapies and diagnostic market is segmented on the basis of type, treatment, major tests, and region.

The market is divided into two categories based on type: endometrial carcinomas and uterine sarcomas. The endometrial carcinomas segment is likely to dominate the highest market share during the forecast period. One of the unique categories of uterine cancer that occurs in the lining of the uterus is endometrial carcinoma. Assessing advancements in diagnostic techniques and tools specific to endometrial carcinomas, including liquid biopsies or cutting-edge imaging technologies, offers insights into the diagnostic market within this segment.

The market is divided into five categories based on treatments: immunotherapy, surgery, chemotherapy, follow-up treatment, and radiation therapy. The chemotherapy segment is accounted to grow with the highest market share as chemotherapy is an essential component of uterine cancer treatment, particularly for metastatic or advanced cases. Chemotherapeutic substances are utilized to kill or to slow down the growth of the rapidly dividing cancer cells

Uterine Cancer Therapies and Diagnostic Market- Geographical Insights

North America is likely to dominate the uterine cancer therapeutics and diagnostics market in the future. The growing awareness and rising incidence among the general population is the prime reason for the market growth in this region. Additionally, faster adoption of new technologies in the economy is boosting the overall growth of the market studied. Moreover, the European region is accounted to dominate the market due to the changing lifestyles of women in these countries. In aged women prevalence of uterine cancer is more common.

Uterine Cancer Therapies and Diagnostic Market- Competitive Landscape:

The uterine cancer therapeutic and diagnostic market is highly competitive, with several medical device manufacturers, pharmaceutical companies, and research institutions actively participating. Advancements in diagnostic and therapeutic technologies and new entrants continue to influence the market. Additionally, for cancer treatment and screening supportive government initiatives and healthcare policies, boost the overall market growth of the uterine cancer therapeutic and diagnostic. In the field of oncology, ongoing research and development activities lead to the development of diagnostic tools and innovative therapies. For instance, in June 2023, Pfizer Inc. announced that DUAVEE® an estrogen-based menopause hormone therapy, is now back in stock in the United States, with better packaging, following a voluntary recall. The recall was due to a concern with the packaging and was not based on any safety and efficacy concerns with the product itself.

Recent Developments:

For instance, in April 2021, Roche announced the U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. Testing can examine patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC MARKET KEY PLAYERS

  • Ariad Pharmaceuticals
  • AstraZeneca PLC
  • Siemens Healthcare Inc.
  • Abbott Laboratories
  • Eli Lilly and Company
  • Becton Dickinson & co
  • Roche Ltd.
  • GlaxoSmithKline Plc
  • Ability Pharma
  • Merck & Co.
  • BioMerieux S.A.
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Sanofi

GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC MARKET, BY TYPE

  • Endometrial carcinomas
  • Uterine sarcomas

GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC MARKET, BY TREATMENT

  • Immunotherapy
  • Surgery
  • Chemotherapy
  • Follow-up Treatment
  • Radiation therapy

GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC MARKET, BY MAJOR TESTS

  • Hysteroscopy
  • Biopsy
  • Pelvic Ultrasound
  • CT Scan
  • Dilation and curettage
  • Others

GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Uterine Cancer Therapies and Diagnostic Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Uterine Cancer Therapies and Diagnostic Market Snippet by Type
    • 2.1.2. Uterine Cancer Therapies and Diagnostic Market Snippet by Treatment
    • 2.1.3. Uterine Cancer Therapies and Diagnostic Market Snippet by Major tests
    • 2.1.4. Uterine Cancer Therapies and Diagnostic Market Snippet by Country
    • 2.1.5. Uterine Cancer Therapies and Diagnostic Market Snippet by Region
  • 2.2. Competitive Insights

3. Uterine Cancer Therapies and Diagnostic Key Market Trends

  • 3.1. Uterine Cancer Therapies and Diagnostic Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Uterine Cancer Therapies and Diagnostic Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Uterine Cancer Therapies and Diagnostic Market Opportunities
  • 3.4. Uterine Cancer Therapies and Diagnostic Market Future Trends

4. Uterine Cancer Therapies and Diagnostic Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Uterine Cancer Therapies and Diagnostic Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Uterine Cancer Therapies and Diagnostic Market Landscape

  • 6.1. Uterine Cancer Therapies and Diagnostic Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Uterine Cancer Therapies and Diagnostic Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2022&2030 (%)
    • 7.1.2. Endometrial carcinomas
    • 7.1.3. Uterine sarcomas

8. Uterine Cancer Therapies and Diagnostic Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2022&2030 (%)
    • 8.1.2. Immunotherapy
    • 8.1.3. Surgery
    • 8.1.4. Chemotherapy
    • 8.1.5. Follow-up Treatment
    • 8.1.6. Radiation therapy

9. Uterine Cancer Therapies and Diagnostic Market - By Major tests

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Major tests, 2022&2030 (%)
    • 9.1.2. Hysteroscopy
    • 9.1.3. Biopsy
    • 9.1.4. Pelvic Ultrasound
    • 9.1.5. CT Scan
    • 9.1.6. Dilation and curettage

10. Uterine Cancer Therapies and Diagnostic Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022&2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Uterine Cancer Therapies and Diagnostic Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Uterine Cancer Therapies and Diagnostic Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Uterine Cancer Therapies and Diagnostic Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Uterine Cancer Therapies and Diagnostic Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Uterine Cancer Therapies and Diagnostic Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Uterine Cancer Therapies and Diagnostic Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Ariad Pharmaceuticals
    • 11.2.2. AstraZeneca PLC
    • 11.2.3. Siemens Healthcare Inc.
    • 11.2.4. Abbott Laboratories
    • 11.2.5. Eli Lilly and Company
    • 11.2.6. Becton Dickinson & co
    • 11.2.7. Roche Ltd.
    • 11.2.8. GlaxoSmithKline Plc
    • 11.2.9. Ability Pharma
    • 11.2.10. Merck & Co.
    • 11.2.11. BioMerieux S.A.
    • 11.2.12. Novartis AG
    • 11.2.13. F. Hoffmann-La Roche AG
    • 11.2.14. Sanofi

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Uterine Cancer Therapies and Diagnostic Market: Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Uterine Cancer Therapies and Diagnostic Market, by Type2018-2030 (USD Million)
  • TABLE Uterine Cancer Therapies and Diagnostic Market: TreatmentSnapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment
  • TABLE Global Uterine Cancer Therapies and Diagnostic Market, by Treatment2018-2030 (USD Million)
  • TABLE Uterine Cancer Therapies and Diagnostic Market: Major tests Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Major tests
  • TABLE Global Uterine Cancer Therapies and Diagnostic Market, by Major tests 2018-2030 (USD Million)
  • TABLE Uterine Cancer Therapies and Diagnostic Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Uterine Cancer Therapies and Diagnostic Market, by Region 2018-2030 (USD Million)
  • TABLE North America Uterine Cancer Therapies and Diagnostic Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Uterine Cancer Therapies and Diagnostic Market, by Type, 2018-2030 (USD Million)
  • TABLE North America Uterine Cancer Therapies and Diagnostic Market, by Treatment, 2018-2030 (USD Million)
  • TABLE North America Uterine Cancer Therapies and Diagnostic Market, by Major tests, 2018-2030 (USD Million)
  • TABLE Europe Uterine Cancer Therapies and Diagnostic Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Uterine Cancer Therapies and Diagnostic Market, by Type, 2018-2030 (USD Million)
  • TABLE Europe Uterine Cancer Therapies and Diagnostic Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Europe Uterine Cancer Therapies and Diagnostic Market, by Major tests, 2018-2030 (USD Million)
  • TABLE Asia Pacific Uterine Cancer Therapies and Diagnostic Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Uterine Cancer Therapies and Diagnostic Market, by Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Uterine Cancer Therapies and Diagnostic Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Asia Pacific Uterine Cancer Therapies and Diagnostic Market, by Major tests, 2018-2030 (USD Million)
  • TABLE Latin America Uterine Cancer Therapies and Diagnostic Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Uterine Cancer Therapies and Diagnostic Market, by Type, 2018-2030 (USD Million)
  • TABLE Latin America Uterine Cancer Therapies and Diagnostic Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Latin America Uterine Cancer Therapies and Diagnostic Market, by Major tests, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Uterine Cancer Therapies and Diagnostic Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Uterine Cancer Therapies and Diagnostic Market, by Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Uterine Cancer Therapies and Diagnostic Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Uterine Cancer Therapies and Diagnostic Market, by Major tests, 2018-2030 (USD Million)